OLMA Olema Pharmaceuticals Inc
Price (delayed)
$4.99
Market cap
$285.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.18
Enterprise value
$251.73M
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is
Highlights
The debt has declined by 35% year-on-year and by 13% since the previous quarter
OLMA's EPS is up by 6% YoY but it is down by 6% QoQ
OLMA's quick ratio has dropped by 60% year-on-year and by 22% since the previous quarter
Olema Pharmaceuticals's net income has decreased by 28% YoY and by 12% from the previous quarter
Key stats
What are the main financial stats of OLMA
Market
Valuations
Earnings
Shares outstanding
57.3M
Market cap
$285.92M
Enterprise value
$251.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.44
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$135.91M
Net income
-$122.68M
EBIT
-$122.68M
EBITDA
-$121.13M
Free cash flow
-$96.7M
Per share
Balance sheet
Liquidity
EPS
-$2.18
EPS diluted
-$2.18
Free cash flow per share
-$1.69
Book value per share
$3.47
Revenue per share
$0
TBVPS
$4.02
Total assets
$230.17M
Total liabilities
$31.26M
Debt
$1.7M
Equity
$198.91M
Working capital
$187.29M
Debt to equity
0.01
Current ratio
7.1
Quick ratio
7
Net debt/EBITDA
0.28
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-47.9%
Return on equity
-53.6%
Return on invested capital
-63.4%
Return on capital employed
-61.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OLMA stock price
How has the Olema Pharmaceuticals stock price performed over time
Intraday
-1.77%
1 week
0.4%
1 month
-9.27%
1 year
-64.02%
YTD
-14.41%
QTD
-14.41%
Financial performance
How have Olema Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$135.91M
Net income
-$122.68M
Gross margin
N/A
Net margin
N/A
The operating income has decreased by 34% YoY and by 12% QoQ
Olema Pharmaceuticals's net income has decreased by 28% YoY and by 12% from the previous quarter
Growth
What is Olema Pharmaceuticals's growth rate over time
Valuation
What is Olema Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OLMA's EPS is up by 6% YoY but it is down by 6% QoQ
OLMA's price to book (P/B) is 52% less than its last 4 quarters average of 3.0 and 37% less than its 5-year quarterly average of 2.3
Olema Pharmaceuticals's equity has decreased by 28% YoY and by 12% from the previous quarter
Efficiency
How efficient is Olema Pharmaceuticals business performance
Olema Pharmaceuticals's ROE has decreased by 21% from the previous quarter and by 13% YoY
The return on assets has declined by 19% since the previous quarter and by 10% year-on-year
The return on invested capital has declined by 11% since the previous quarter
Dividends
What is OLMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OLMA.
Financial health
How did Olema Pharmaceuticals financials performed over time
Olema Pharmaceuticals's total liabilities has soared by 77% YoY and by 14% from the previous quarter
OLMA's current ratio has dropped by 60% year-on-year and by 22% since the previous quarter
The debt is 99% smaller than the equity
The debt has declined by 35% year-on-year and by 13% since the previous quarter
Olema Pharmaceuticals's equity has decreased by 28% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.